According to the American Cancer Society, more than 1.6 million new cancer cases will be diagnosed in 2012, and more than 577,000 Americans are expected to die of cancer this year.

Pompe disease is a rare condition, with a global incidence rate estimated to be between 1 in 40,000 (0.0025%) and 1 in 300,000 (0.0003%) live births.1 According to a study published in 1998, the annual incidence of Pompe disease in New York City was estimated to be approximately 1 in 40,000 births, and approximately 90 babies are assumed born with Pompe disease in the United States annually.2 A similar incidence rate was found in the Dutch population (1 in 40,000 births), a relatively lower rate was found among the Chinese (1 in 50,000 births; 0.0020%), and a higher ra

Beyond “Patient Amusement”: New Treatments and Genetic Disease

Atrial fibrillation (AF) is a significant health and cost concern for the Medicare population (age ≥65 years), because of its association with an increased risk for stroke and all-cause mortality.1 The risk for stroke in patients with AF is almost 5-fold higher than in patients without AF.2 One of every 6 strokes in the United States is associated with AF,3 and strokes in patients with AF are more severe and disabling than in patients without AF.4 The prevalence of AF in the Medicare population increased from 3.2% in 1992 to 6.0% in 2002.5

Warfarin Utilization in Medicare Patients with Nonvalvular Atrial Fibrillation: Sentinel Data from an Administrative Claims Database

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disorder and the most common form of inflammatory arthritis.1 RA affects 1% of the population, most often adults aged 40 to 70 years.2 Recent epidemiologic data indicate that the incidence of RA in women has risen in the past 10 years.3 Because RA affects many individuals who are of working age and remains a major cause of disability, the economic burden of RA adds a significant cost not only to patients and their families, but also to society as a whole.1,4 In addition, reduced quality of

Biologic Therapies for Rheumatoid Arthritis: It's All about Value

Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by abnormally high blood pressure (ie, hypertension) in the pulmonary artery, with 1000 new cases being diagnosed annually in the United States, based on a 2009 report.1 Because of the complex nature of PAH and its treatments, healthcare providers must closely follow patients with PAH; depending on the stage of the illness, patients should generally be seen by a physician every 3 to 6 months according to the 2009 American College of Cardiology Foundation Task Force on Expert Consensus Documents and the

The Challenges of Pulmonary Arterial Hypertension Management: Potential Benefits of Removing Monthly Testing

Advances in biotechnology have led to the development of new medical therapies for a variety of diseases, including many types of cancers and autoimmune diseases (eg, rheumatoid arthritis). Among these agents are biologics, also known as specialty pharmaceuticals. These drugs represent the fastest-growing segment of pharmaceuticals. Employers sponsor a significant proportion of plans that provide healthcare benefits, including biologics.

An Educated Consumer Is Our Best Customer

Patient access to healthcare resources is an important topic of healthcare discussion, research, and reform in the United States.1,2 Access issues are usually framed in the context of patients having health insurance, as the quality of health insurance facilitates patient access to necessary medical and pharmaceutical therapies.2 Although patient access to medications is essential, formulary management strategies may introduce barriers aimed at restricting utilization, including curbing patient demand by increasing the cost borne by the patient or providing incentives

We Need More Research on True Value-Based Benefit Design that Will Improve Outcomes and Control Costs

Chest pain, or angina pectoris, is the primary symptom of coronary artery disease (CAD), or chronic heart disease, a leading cause of morbidity and mortality in the United States.

Medical Claims Data Can Inform Coverage Decisions in Managed Care Health Plans

Rhonda Greenapple, MSPHDiabetes is an important disease state causing significant morbidity and mortality throughout the United States and worldwide. The current obesity epidemic, together with the US aging population, is fueling the rapid increase in diabetes prevalence.

We Must All Engage in the Diabetes Challenge: A Lifelong Journey, with No Silver Bullet

Nowhere is this caveat from David Blumenthal, MD, MPP, the former National Coordinator for Health Information Technology, more applicable than in the emergency department setting. Although originally designed as the section of a hospital where only the most acutely ill persons should seek care for their maladies, the emergency department has become much more than that. It now serves as the primary care provider for many who have no such physician outside the emergency department.2,3

Health as a Sustainability Strategy: We Need a Healthcare System Focused on Keeping People Healthy Rather than Adding Layers to the Already Too Long, Fragmented Supply Chain
Page 9 of 13
Results 81 - 90 of 126
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME